Avid Bioservices

Yahoo Finance • 11 months ago

Insider Stock Buying Reaches US$527.5k On Avid Bioservices

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Avid Bioservices, Inc.'s (NASDAQ:CDMO) instance, it's good news for shareholders. While insider transactions... Full story

Yahoo Finance • last year

Avid Bioservices Inc (CDMO) Adjusts Fiscal 2024 Revenue Guidance Amidst Second Quarter Challenges

Avid Bioservices Inc (NASDAQ:CDMO) reports a second-quarter revenue of $25.4 million, a decrease from the previous year. The company has signed $35 million in net new business orders, resulting in a $199 million backlog. Adjustment of fisc... Full story

Yahoo Finance • last year

Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs

TUSTIN, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality developme... Full story

Yahoo Finance • last year

Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility

Newly Launched CGMP Manufacturing Suites Undergoing Final Environmental Monitoring and Performance Qualification with Grand Opening Planned for January 2024 Completion of CGT Facility Brings Company’s Total Revenue Generating Capacity to... Full story

Yahoo Finance • last year

Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference

TUSTIN, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality developm... Full story

Yahoo Finance • last year

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023

-- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million -- -- Cell and Gene Therapy Facility Expansion Remains on Schedule for Opening by End of Calend... Full story

Yahoo Finance • last year

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023

TUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services... Full story

Yahoo Finance • 2 years ago

Q4 2023 Avid Bioservices Inc Earnings Call

Participants Daniel R. Hart; CFO; Avid Bioservices, Inc. Matthew Kwietniak Nicholas Stewart Green; President, CEO & Director; Avid Bioservices, Inc. Jacob K. Johnson; MD & Analyst; Stephens Inc., Research Division Matthew Gregory Hewi... Full story

Yahoo Finance • 2 years ago

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023

-- Fourth Quarter and Full Year Revenue of $39.8 Million and $149.3 Million, Respectively, Both Represent a Record-High Achievement -- -- Signed $55 Million in Net New Business Orders Resulting in a Record-High Backlog of $191 Million --... Full story

Yahoo Finance • 2 years ago

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023

TUSTIN, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services... Full story

Yahoo Finance • 2 years ago

Avid Bioservices to Participate in RBC Capital Markets Global Healthcare Conference

TUSTIN, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality developmen... Full story

Yahoo Finance • 2 years ago

STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. “We are pleased to welcome D... Full story

Yahoo Finance • 2 years ago

Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers

Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing Suites within Myford Facility First Customer Project in Newly Expanded Capacity to Kick-Off This Month Company Also Announces Completion... Full story

Yahoo Finance • 2 years ago

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments

-- Recorded Third Quarter Revenue of $38.0 Million, a 21% Increase Compared to Prior Year Quarter -- -- Signed $67 Million in Net New Business Orders Resulting in a Backlog of $176 million, an Increase of 26% Year-Over-Year -- -- Mammali... Full story

Yahoo Finance • 2 years ago

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2023 After Market Close on March 13, 2023

TUSTIN, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services... Full story

Yahoo Finance • 2 years ago

13 High Growth Pharma Stocks that are Profitable

In this piece, we will take a look at 13 high growth pharma stocks that are profitable. For more stocks, head on over to 5 High Growth Pharma Stocks that are Profitable. One industry that has rapidly evolved with time and impacted million... Full story

Yahoo Finance • 2 years ago

Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments

-- Recorded Second Quarter Revenue of $34.8 Million -- -- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year -- -- Mammalian Cell Facilities and Cell and Gene Therapy... Full story

Yahoo Finance • 2 years ago

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022

TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services... Full story

Yahoo Finance • 2 years ago

Avid Bioservices Appoints Oksana Lukash as Vice President, People

TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality developme... Full story

Yahoo Finance • 2 years ago

Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference

TUSTIN, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality developme... Full story